Human normal immunoglobulin (IVIg)
Intravenous immunoglobulin is pooled antibody from many blood donors. People with chronic lymphocytic leukaemia or myeloma whose own antibody levels have collapsed, and who keep getting bacterial infections despite antibiotics, receive it as replacement.
Overview
Human normal immunoglobulin for intravenous use is authorised in the EU as Kiovig (authorised 19 January 2006; marketing authorisation holder Takeda Manufacturing Austria AG) and Privigen (authorised 24 April 2008; CHMP opinion 21 February 2008; marketing authorisation holder CSL Behring GmbH). The replacement-therapy indications include primary immunodeficiency syndromes and, in cancer care, hypogammaglobulinaemia with recurrent bacterial infections in patients with chronic lymphocytic leukaemia in whom prophylactic antibiotics have failed, and in plateau-phase multiple myeloma patients who have failed to respond to pneumococcal immunisation; the products also carry immunomodulation indications outside oncology.
Replacement of antibodies in patients whose own production has failed; in cancer care, for hypogammaglobulinaemia with recurrent bacterial infections in chronic lymphocytic leukaemia after prophylactic antibiotics have failed and in plateau-phase multiple myeloma after failure to respond to pneumococcal immunisation (indication wording, EMA).
1.Human normal immunoglobulin (IVIg) binds its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2006 | Replacement therapy in hypogammaglobulinaemia with recurrent bacterial infections in CLL (after failed antibiotic prophylaxis) and plateau-phase multiple myeloma (after failed pneumococcal immunisation); primary immunodeficiency · Kiovig authorised 19 Jan 2006 (Takeda); Privigen 24 Apr 2008 (CSL Behring) |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Human normal immunoglobulin" OR ABSTRACT:"Human normal immunoglobulin" OR TITLE:"IVIg" OR ABSTRACT:"IVIg" OR TITLE:"Privigen" OR ABSTRACT:"Privigen" OR TITLE:"Kiovig" OR ABSTRACT:"Kiovig" OR TITLE:"human normal immunoglobulin IVIg" OR ABSTRACT:"human normal immunoglobulin IVIg" OR TITLE:"human normal immunoglobulin" OR ABSTRACT:"human normal immunoglobulin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Human normal immunoglobulin (IVIg), not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBurosumab
Shares the tags ema-register, supportive.
- TreatmentEpoetin theta
Shares the tags ema-register, supportive.
- TreatmentFentanyl (transmucosal, for breakthrough cancer pain)
Shares the tags ema-register, supportive.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda, Multiple myeloma.
- TreatmentPalifermin
Shares Multiple myeloma and the tag supportive.
- TreatmentRasburicase
Shares Chronic lymphocytic leukaemia and the tag supportive.
- TechnologyCancer-associated thrombosis prevention and treatment
Shares Multiple myeloma and the tag supportive.
- TreatmentPlerixafor
Shares Multiple myeloma and the tag supportive.